Search Results - "Móciková, H"

OUTCOMES OF THE TREATMENT AFTER ANTI‐CD19 CAR‐T THERAPY FAILURE IN PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMA—ANALYSIS OF DATA FROM THE CZECH REPUBLIC by Sýkorová, A., Polgárová, K., Folber, F., Ďuraš, J., Móciková, H., Steinerová, K., Obr, A., Belada, D., Smolej, L., Trněný, M., Pytlík, R.

Get full text

PREDICTIVE VALUE OF PRIMA‐PROGNOSTIC INDEX (PRIMA‐PI) IN FIRST RELAPSE OF FOLLICULAR LYMPHOMA by Ďuraš, J., Procházka, V., Belada, D., Janíková, A., Móciková, H., Kopečková, K., Hájek, R., Trněný, M.

Get full text

DA‐EPOCH‐R VERSUS R‐CHOP IN HIGH RISK DLBCL PATIENTS: ANALYSIS OF THE CZECH LYMPHOMA STUDY GROUP (CLSG) by Šimkovič, M., Móciková, H., Ďuraš, J., Kamarádová, K., Štěpánková, P., Janíková, A., Michalka, J., Žák, P., Belada, D., Trněný, M.

Get full text

P676: LOW‐DOSE FCR COMPARED TO BR IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT TP53 ABERRATIONS: A REAL – WORLD RETROSPECTIVE ANALYSIS BY THE CZECH CLL STUDY GROUP by Smolej, L., Brychtová, Y., Cmunt, E., Oršulová, M., Vodárek, P., Dostál, M., Turcsányi, P., Urbanová, R., Panovská, A., Zuchnická, J., Mihályová, J., Lysák, D., Brejcha, M., Móciková, H., Klásková, K., Šimkovič, M., Špaček, M., Doubek, M.

Get full text

LOTIS‐5, AN ONGOING PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE WITH RITUXIMAB (LONCA‐R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R / R DLBCL by Carlo‐Stella, C., Kwiatek, M., Chung, M., Móciková, H., Bergua‐Burgues, J. M., Gao, S., Grosicki, S., Stathis, A., Toupin, D., Wang, Y., Wang, L., Hamadani, M.

Get full text

Burkitt lymphoma–multicenter retrospective data analysis from the Czech Lymphoma Study Group–NiHiL project by Sýkorová, A., Pytlík, R., Móciková, H., Janíková, A., Procházka, V., Belada, D., Šálek, D., Benešová, K., Klener, P., Ďuraš, J., Smolej, L., Šimkovič, M., Campr, V., Vosáhlová, V., Blahovcová, P., Trněný, M.

Get full text

Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL) by Janikova, A., Michalka, J., Chloupkova, R., Kopalova, N., Campr, V., Kamaradova, K., Kren, L., Belada, D., Benesova, K., Dlouha, J., Klener, P., Procházka, V., Mocikova, H., Duras, J., Trneny, M.

“…Mature T cell lymphomas (MTCLs) have worse prognosis, and in contrast to B cell lymphomas, there is no universal marker like CD20 with exception of ALK and…”
Get full text

Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study by Mocikova, H., Obrtlikova, P., Vackova, B., Trneny, M.

“…Routine positron emission tomography (PET) in follow-up of Hodgkin lymphoma (HL) after treatment is still controversial. The aim of this retrospective study…”
Get full text

ANALYSIS OF PATIENTS IN THE FIRST RELAPSE OR PROGRESSION OF T‐CELL LYMPHOMA. REAL WORLD DATA FROM CZECH LYMPHOMA STUDY GROUP REGISTRY (NIHIL) by Janikova, A., Belada, D., Klanova, M., Chloupkova, R., Kopalova, N., Campr, V., Kamaradova, K., Prochazka, V., Benesova, K., Mocikova, H., Duras, J., Trneny, M.

Get full text

BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED CD30‐POSITIVE PERIPHERAL T‐CELL LYMPHOMAS: REAL‐WORLD DATA by Klanova, M., Sykorova, A., Janikova, A., Mocikova, H., Duras, J., Prochazka, V., Pukyova, J., Klener, P., Belada, D., Kopalova, N., Benesova, K., Campr, V., Blahovcova, P., Trneny, M.

Get full text

HOW WE ARE SUCCESSFUL IN THERAPY OF T‐CELL LYMPHOMA PATIENTS (≥70 YEARS). REAL‐WORDL ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP REGISTRY (NIHIL) by Janikova, A., Klanova, M., Belada, D., Chloupkova, R., Campr, V., Kamaradova, K., Kopalova, N., Benesova, K., Prochazka, V., Mocikova, H., Duras, J., Trneny, M.

Get full text

Outcome of elderly patients with classical Hodgkin’s lymphoma by Sykorova, A., Mocikova, H., Lukasova, M., Koren, J., Stepankova, P., Prochazka, V., Belada, D., Klaskova, K., Gaherova, L., Chroust, K., Buresova, L., Markova, J.

“…•Risk factors for OS and PFS are lymphopenia<8 % and anthracycline-free chemotherapy.•CIRS > 3 is an independent risk factor for OS but not for PFS in elderly…”
Get full text

Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL) by McDonald, A., Verburgh, E., Gotti, M., Pinto, A., Zaucha, J., Ivanov, V., Melnichenko, V., Mocikova, H., Ozcan, M., Patti, C., Farias, J., Goncalves, I., Kuchkova, O., Mayer, J., Saydam, G., Tomassetti, S., Pathiraja, K., Ryland, K., Chakraborty, S., Jurczak, W.

Get full text

Long‐term efficacy and safety of zanubrutinib (ZANU) in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB‐3111‐214) trial by Trotman, J., Tedeschi, A., Hu, B., Linton, K. M., McKay, P., Leitch, S., Jin, J., Sun, M., Sobieraj‐Teague, M., Zinzani, P. L., Browett, P., Thieblemont, C., Liberati, A. M., Bachy, E., Cavallo, F., Costello, R., Iyengar, S., Marasca, R., Mociková, H., Kim, J. S., Talaulikar, D., Liang, Z., Xu, J., Tankersley, C., Delarue, R., Co, M., Opat, S.

Get full text

COGNITIVE IMPAIRMENT AFTER 6 AND 12 MONTHS OF HODGKIN LYMPHOMA TREATMENT by Mocikova, H., Gaherova, L., Fayette, D., Jurickova, V., Horacek, J., Kozak, T.

Get full text

PERIPHERAL T‐CELL LYMPHOMAS INVOLVING CENTRAL NERVOUS SYSTEM: A REPORT FROM THE CZECH LYMPHOMA STUDY GROUP REGISTRY by Mocikova, H., Pytlik, R., Benesova, K., Janikova, A., Duras, J., Sykorova, A., Steinerova, K., Prochazka, V., Campr, V., Belada, D., Dlouha, J., Trneny, M.

Get full text

Prognostic significance of absolute lymphocyte count and lymphocyte subsets in lymphomas by Mociková, H

“…Lymphocytopenia is a poor prognostic marker in initial staging of non- Hodgkin lymphomas (below 1.0 x 10(9)/l) and Hodgkin lymphoma (below 0.6 x 10(9)/l) and…”
Get more information

T‐CELL LYMPHOMA IN THE ELDERLY PATIENTS. WHO IS YOUNG, OLD, AND ELDERLY? by Janikova, A., Chloupkova, R., Klener, P., Benesova, K., Campr, V., Belada, D., Sykorova, A., Prochazka, V., Kopalova, N., Hamouzova, J., Pirnos, J., Duras, J., Mocikova, H., Trneny, M.

Get full text

PROGNOSTIC VALUE OF THE INTERVAL BETWEEN RELAPSE AND THERAPY INITIATION IN DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS. ANALYSIS FROM THE CZECH LYMPHOMA STUDY GROUP DATABASE by Janikova, A., Chloupkova, R., Campr, V., Kopalova, N., Klener, P., Benesova, K., Hamouzova, J., Belada, D., Sykorova, A., Prochazka, V., Pirnos, J., Duras, J., Mocikova, H., Michalka, J., Trneny, M.

Get full text

IS IT RADIOTHERAPY NECESSARY FOR PRIMARY MEDIASTINAL B‐CELL LYMPHOMA (PMBL) PATIENTS ACHIEVING PET NEGATIVITY AFTER IMMUNOCHEMOTHERAPY? by Trneny, M., Polgarova, K., Janikova, A., Belada, D., Prochazka, V., Duras, J., Mocikova, H., Steinerova, K., Campr, V., Blahovcova, P., Petrova, M., Zogala, D., Ptacnik, V.

Get full text